Bioeq’s Lucentis Biosimilar Is Given EU Go-Ahead
Launch Dates And Financial Terms Of A Marketing Deal With Teva Remain Under Wraps
Executive Summary
Bioeq’s Ranivisio ranibizumab biosimilar has gained European Commission authorization for all innovator indications including wet AMD, the leading cause of blindness among over-65s.
You may also be interested in...
Xbrane Estimates Q1 2023 Resubmission For US Lucentis Biosimilar
Having first expected to resubmit the filing by the end of this year, a delay to a key report means Xbrane now expects to deliver its new biologics license application to the FDA during Q1 2023.
Five Things Facing Teva’s New CEO Richard Francis
With Teva clearing up early who will replace outgoing president and CEO Kåre Schultz, Generics Bulletin looks at five issues that await his replacement, the former Sandoz head Richard Francis.
Stada And Xbrane Gain EU All-Clear For Ranibizumab Biosimilar
The European Commission has approved Stada and Xbrane’s Ximluci ranibizumab biosimilar, the third Lucentis rival to be approved in the region so far. The companies are aiming to launch in early 2023 in selected European markets.